Although it is the largest organ of the human body, skin is often not considered in discussions of drug metabolism. However, there is growing evidence that most common drug-metabolizing enzymes are expressed in the skin. Evidence for expression of cytochromes P450, flavin monooxygenases, glutathione-S-transferases, N-acetyltransferases, and sulfotransferases in human skin and skin cells are presented. Additional discussion is focused on the evidence of actual metabolism of drugs. Finally, the potential clinical implications of metabolism within the skin are discussed briefly.
Representing the largest organ in the human body, skin provides an important barrier role in protecting the body from external chemicals and pathogens that would otherwise impair critical functions needed for survival. Comprised of a complex cellular network, skin is capable of many metabolic functions common to visceral organs, including the biotransformation of drugs that penetrate through its most external layer. In addition to being an important target for pharmacotherapy, delivery through the skin is increasingly used as an effective means of delivering drugs to the systemic circulation. It is also evident that biotransformation within the skin may be an essential step to manifesting cutaneous toxicity to certain drugs and chemicals. Hence, an understanding of the capacity and impact of drug biotransformation within skin is an important component in assessing pharmacotherapy directed to or through the cutaneous environment. In the present article, discussion will be limited to evidence for biotransformation of drugs generated specifically in human skin or skin cells. Although many investigations have probed the ability of skin from numerous species to metabolize a variety of environmental chemicals, the focus of the present review is on evidence for metabolism of therapeutic agents. The reader is referred to the recent review of Oesch et al. (2007) for a comparison of xenobiotic-metabolizing enzymes in the skin of various species.
Overview of the Structure and Function of Skin
Existing as a dynamic and flexible barrier, human skin serves a multifaceted role as the organ with the greatest exposure to the external environment. In addition to providing the primary means for tactile evaluation of the immediate surroundings, skin serves a critical role in thermoregulation of the body. The plethora of infectious diseases with cutaneous manifestations attests to the important sentinel role of skin in protecting the body from bacterial, fungal, and viral pathogens. Although this diversity of function is recognized, it is not surprising that skin is populated by numerous types of specialized cells (see Table 1 ) that enable dynamic interaction with the internal and external environment. Because studies assessing the role of skin in drug metabolism often use model cells, it is important to begin this review with a brief discussion of skin structure and function.
Three identifiable layers comprise human skin: epidermis, dermis, and hypodermis. Constituting the outermost region of the skin, the epidermis is primarily composed of keratinocytes (KCs), which make up 90 to 95% of cells in this layer of skin (Haake et al., 2000) . Programmed differentiation of KCs as they progress through the epidermal layer produces a stratification of cell phenotype, ultimately giving rise to a highly keratinized dead cell at the surface of the skin. Whereas this terminally differentiated stage produces the initial skin barrier and is important for reducing water loss, cells at earlier stages of differentiation provide important regulatory signals for immune responses in the cutaneous environment. Due to their abundance and ready access from human tissue samples, KCs represent the most common skin cell used to assess skin metabolism of drugs and chemicals.
As seen in other "ports of entry" to the body, the epidermis is punctuated by the presence of resident dendritic cells, which are known as Langerhans cells (LCs). Found in close association with KCs through E-cadherin receptors, these cells engulf antigens and, in the presence of appropriate stress signals, mobilize for migration to draining lymph nodes (Romani et al., 2003) . Once present in the lymph node, these LCs present antigen to T cells, causing a clonal expansion of antigen-specific T cells that migrate to the cutaneous environment via the vascular system. Hence, LCs have the capacity to carry drug-protein conjugates formed in situ from the cutaneous environment to lymph organs that are essential in mediating a systemic response.
Skin pigmentation is attributed to another important cell type present in the epidermis-the melanocyte. The active production of melanin by these cells provides a component of the protection from UV light afforded by the skin. There is evidence for intercellular communication between KCs and melanocytes in the skin, although the full nature of this is unclear at present (Nordlund and Boissy, 2000) . A final cell type of importance in the epidermis is Merkel cells, which serve as the mechanoreceptors for the skin. As expected, the density of these cells is highest in regions of the skin that provide the greatest tactile response (e.g., fingertips). These cells have also been found in association with KCs in specific regions of the skin (e.g., hair bulb), suggesting that intercellular communication may occur within this pairing.
Possessing an extensive vascular network, as well as a dense network of fibrils, the dermis endows the skin with tensile strength that provides mechanical resistance. The primary cells of the dermis are fibroblasts, which secrete the extracellular matrix that creates the aforementioned fibril network (Haake et al., 2000) . Microscopically, they are readily differentiated from KCs by their elongated nature. In addition to fibroblasts, the dermis possesses a mononuclear phagocytic system comprised of monocytes, macrophages, and dermal dendrocytes. As immunocompetent cells, dermal dendrocytes play an important role in fibrotic and inflammatory conditions of the skin. An additional cell type, mast cells, is present throughout the dermal layer and serves as the primary effector cells for allergic reactions.
The hypodermis plays several important roles, including insulation, cushioning, and energy supply. Composed primarily of adipocytes, this layer of skin also possesses the apocrine and eccrine sweat glands.
Evidence for the Expression of Drug-Metabolizing Enzymes in Skin and Skin Cells
The first line of evidence suggesting that drug metabolism may occur in human skin arises from studies that demonstrate the expression of drug-metabolizing enzymes in cutaneous tissue. Studies have varied in terms of the sources of tissue, ranging from skin biopsies to cultures of isolated cells from skin. Tables 2 and 3 summarize the evidence for specific enzyme expression from these various sources. As will be discussed, whereas message expression has been detected for many genes of drug-metabolizing enzymes, evidence for expression of the actual enzyme is more limited.
Interpretation of studies that present evidence for expression of enzymes in particular subpopulations of skin cells must be undertaken cautiously. Isolation of an uncontaminated sample of a specific skin cell type is experimentally challenging. In our experience, commercially available sources of specific cell types may be contaminated with a low frequency of other cell types. Most studies noted herein have not incorporated (or at least described) rigorous assessment of cell populations to assure the homogeneity of the cell samples. Hence, low-level contamination of samples by other skin cell types may result in an erroneous conclusion of expression of enzyme in the cell type of interest. Thus, whereas the studies referenced in Tables 2 and 3 provide ample evidence for expression of these enzymes in skin cells, the certainty of expression in specific cell types is less than uniform.
Cytochromes P450. Because cytochromes P450 (P450) are the most abundant of the drug-metabolizing enzymes found in liver, numerous investigations have naturally focused on probing for the presence of members of this enzyme family in human skin and skin cells. Early work focused on demonstrating P450-like activity and responsiveness to some inducers of these enzymes. As molecular biology techniques have advanced, probes for specific enzymes have been used and demonstrated the presence of numerous members of this important enzyme family. Table 2 provides a summary of evidence to date for the presence of these enzymes in human skin biopsy samples or cultures of specific skin cells, together with representative references supporting these findings.
Evidence for the presence of the CYP1A enzymes has been sought by several investigators. Early studies demonstrating the ability of animal skin to metabolize benzo[a]pyrene suggested expression of CYP1A1 in skin. Indeed, CYP1A1 mRNA has been found in all human skin sources probed to date, although data supporting expression of CYP1A1 protein is limited to KCs (Baron et al., 2001; Saeki et al., 2002; Yengi et al., 2003) . In contrast, studies probing for CYP1A2 mRNA have found that message for expression of this gene in skin or skin cells is undetectable (Baron et al., 2001; Saeki et al., 2002) . CYP1B1 mRNA has been readily detected in skin biopsy samples and all skin cells examined to date (Baron et al., 2001; Saeki et al., 2002; Smith et al., 2003; Yengi et al., 2003) .
Studies probing for the presence of CYP2A6 have been limited to probes for message and in cultured skin cells, with mixed results. Although CYP2A6 mRNA was not detected in KCs, these same investigators observed message in fibroblasts and melanocytes (Saeki et al., 2002) . Studies to date provide evidence for the expression of CYP2B6 mRNA in skin biopsy samples and KCs, with the latter also demonstrating the presence of CYP2B6 protein (Baron et al., 2001; Yengi et al., 2003) .
Probes for the expression of the CYP2C families of enzymes have yielded varied results. Although CYP2C9 mRNA was demonstrated in skin biopsy samples, message was not detectable in KCs or HaCaT cells, an immortalized keratinocyte cell line (Yengi et al., 2003; Vyas et al., 2006a) . Assessment of the expression of CYP2C9 protein in KCs and HaCaT cells by immunoblot were inconclusive (Vyas et al., 2006a) . CYP2C18 and CYP2C19 mRNA have both been detected in skin biopsy samples, although assessment of protein expression has yet to be reported.
Members of the important CYP3A family of enzymes have also been detected in human skin or skin cells. CYP3A5 message and protein have been identified in all skin cell types and biopsy samples probed to date (Baron et al., 2001; Saeki et al., 2002; Smith et al., 2003; Yengi et al., 2003; Vyas et al., 2006a) . It is interesting to note that whereas CYP3A4 message is readily detected in KCs, it has not been observed in HaCaT cells (Vyas et al., 2006a) . Because experimentalists commonly use this immortalized cell line, it is important to recognize that the pattern of metabolism in this cell line may not match that seen in primary cells and in skin itself.
In general, studies that have probed both skin biopsy samples and primary skin cell cultures have been consistent with regard to message expression for specific CYP450s-expression is either present or absent in both sample types. Two exceptions to this observation are CYP2C9 and CYP2D6. Whereas message for these two enzymes was observed in skin biopsy samples from the same laboratory, other investigators have not detected message for these enzymes in cultured KCs. It is unclear at this time whether this difference is due to a loss of gene expression upon culture or methodological differences for probing message between research groups. Hence, data to date suggests that cultured cell models are appropriate for investigations of Other Oxidizing Enzymes. Expression of the flavin monooxygenase (FMO) family of enzymes has been probed by two groups. Whereas FMO1 mRNA was detected in skin biopsy samples, neither message nor protein were detected in cultures of KCs or HaCaT cells (Janmohamed et al., 2001; Vyas et al., 2006b ). In contrast, FMO3 message was expressed in skin biopsy samples, KCs, and HaCaT cells. In addition, FMO3 protein was also detected in primary cultures of KCs. These data indicate that skin cell cultures are a viable model for investigation of biotransformation by FMO3, but that the difference in message expression for FMO1 suggests that skin cell cultures are not a viable model for biotransformation by this enzyme.
Whereas skin cells exhibit peroxidase-like activity, the specific enzymes responsible for this activity are unclear. Although lactoperoxidase (Gorlewska-Roberts et al., 2004) , myeloperoxidase (Uetrecht et al., 1993) , and thyroid peroxidase (Gupta et al., 1992) have been shown to bioactivate arylamines to reactive metabolites in vitro, none of these enzymes seems to be expressed in cultured human KCs (Vyas et al., 2006b) . However, it is noteworthy that peroxidase inhibition reduces the bioactivation of dapsone in human KC cultures (Vyas et al., 2006b )-substantiating a role for peroxidases in cutaneous bioactivation. Further studies are needed to identify the specific peroxidases expressed in human skin and skin cells.
Conjugating Enzymes.
A number of important transferases have been observed in skin biopsy samples or cultured skin cells. In particular, analysis of skin biopsies have revealed the presence of mRNA for members of the glutathione S-transferases (GSTM1 and GSTP1) (Smith et al., 2003) and sulfotransferases (SULT1A1, 1A3, 1E1, 2B1) (Dooley et al., 2000; Falany et al., 2006) . The sulfotransferases have also been observed in primary KC cultures. Consistent with studies in other species, N-acetyltransferase (NAT)-1 message was readily detected in cultures of human KCs and dermal fibroblasts, whereas expression of NAT2 was not evident (Reilly et al., 2000; Bhaiya et al., 2006) . It is interesting to note that an exhaustive Medline search failed to identify any published studies probing for specific drug-metabolizing glucuronosyltransferases in skin or skin cells. It is also unknown whether another important transferase, thiopurine methyltransferase, is expressed in human skin.
Other Enzymes. Whereas nonspecific esterase activity has been demonstrated in human skin and cultured skin cells, investigations into the expression of specific carboxylesterases (CEs) in skin were not identified through an exhaustive literature search. This lack of evidence is somewhat surprising in view of the importance of ester hydrolysis in the activity of a number of marketed topical steroid preparations. To date, the only study that examined the expression of CEs was conducted in an immortalized keratinocyte cell line (HaCaT). In this study, CE-2 mRNA was readily detected, whereas CE-1 message was undetectable (Zhu et al., 2007) . 
Evidence for the Metabolism of Drugs in Skin and Skin Cells
Whereas evidence for the expression of several key drug-metabolizing enzymes in skin provides important evidence that skin is capable of metabolizing drugs, direct in vivo evidence for such metabolism is minimal. Using the microdialysis technique in human subjects, Cross et al. (1998) were able to demonstrate the metabolism of methylsalicylate to salicylate in vivo after topical application. To date, other topical drugs in common use have not been assessed for cutaneous metabolism using this very promising technique. However, there are a number of studies that demonstrate such capacity ex vivo (see Table 4 ). Demonstration of metabolism through metabolite identification in cultured skin cells or skin explants provides evidence for N-acetylation (Reilly et al., 2000; Bhaiya et al., 2006) , N-hydroxylation (Reilly et al., 2000; Bhaiya et al., 2006) , and sulfation (Hamamoto and Mori, 1989; Kudlacek et al., 1995; Anderson et al., 1998) .
The detection of N-acetyl metabolites of p-aminobenzoic acid, dapsone, and sulfamethoxazole in cultured KCs and dermal fibroblasts is consistent with the demonstrated expression of NAT1 message in these cells (Reilly et al., 2000; Bhaiya et al., 2006) . The N-hydroxylation of dapsone and sulfamethoxazole in cultures of KCs is somewhat surprising in view of the absence of CYP2C9 expression in these cells (Reilly et al., 2000) . Although CYP2C9 is the enzyme responsible for the N-hydroxylation of these drugs in liver, it seems that FMO3 and peroxidases are responsible for this metabolism in KCs (Vyas et al., 2006b) . Because the arylhydroxylamine metabolites of these drugs are believe to be involved in the provocation of an immune response (Cribb et al., 1996) , this observation suggests that local biotransformation may be important in these reactions in the skin.
Sulfation of minoxidil was known to be essential for its antihypertensive effects. Deployment of this drug for the promotion of hair growth led to studies that demonstrated that minoxidil sulfate is the active species for hair follicle stimulation. It is not surprising that studies in skin biopsies and cultured KCs have shown that the cutaneous environment is capable of metabolizing minoxidil to its active sulfate metabolite (Hamamoto and Mori, 1989; Kudlacek et al., 1995; Anderson et al., 1998) .
Several oxidative metabolites of propranolol were detected by Ademola and Maibach (1995) in skin biopsy samples. These same investigators found that incubation of fresh human skin was also able to cleave betamethasone 17-valerate, giving rise to the active betamethasone.
Further evidence for the bioactivating capacity of skin is provided by studies which demonstrate that skin cells or skin explants are able to provoke the formation of drug-protein adducts through the bioactivation of parent molecules. For example, incubation of KCs, dermal fibroblasts, or dendritic cells with dapsone or sulfamethoxazole results in the formation of drug-protein adducts that are readily detected by immunochemistry (Roychowdhury et al., , 2007b Bhaiya et al., 2006) . In addition, exposure of human skin explants to dapsone results in the intracellular formation of drug-protein adducts (Roychowdhury et al., 2007a) .
Hence, whereas data are limited, investigations to date provide support for the presumptive capacity of skin to metabolize drugs in vivo. These data suggest a broad array of enzyme expression and activity in the skin. The level of variability of such expression has not been carefully evaluated but may affect the pharmacological and toxicological effect of drugs in the skin.
Clinical Implications of Drug Metabolism in Skin
As abundant evidence demonstrates the presence of important drug-metabolizing enzymes in skin, together with limited data that demonstrate actual metabolism of drugs in cutaneous tissue, it should be expected that biotransformation in skin may affect drug effect and toxicity. The potential clinical implications include application of prodrugs, affect on bioavailability, and cutaneous hypersensitivity.
Bioactivation of Prodrugs. The employment of a prodrug strategy has proven useful for enhancing the bioavailability of drugs after oral administration, as well as the creation of more water-soluble parenteral dosage forms. Similar strategies have been used to enhance penetration of topically applied drugs through the stratum corneum. For example, betamethasone 17-valerate penetrates the stratum corneum more readily than betamethasone. Once it enters the cutaneous environment, the 17-valerate readily isomerizes to the 21-valerate, which is rapidly cleaved by esterases to yield betamethasone (Ademola and Maibach, 1995). Likewise, ester prodrugs of naltrexone have shown greater penetration through the stratum corneum of human skin than naltrexone itself, with almost completed hydrolysis of the prodrug in the epidermis (Stinchcomb et al., 2002) .
Although not initially designed as a prodrug, another example of the importance of bioactivation is the use of minoxidil to promote hair growth in the scalp. Minoxidil must be metabolized to minoxidil sulfate to stimulate hair follicles (Buhl et al., 1990) . The presence of sulfotransferase in skin is essential for the efficacy of this drug.
Bioavailability after Percutaneous Administration. Although permeation of drug through the skin is the primary factor that reduces (Bhaiya et al., 2006) bioavailability, drug entering the cutaneous environment is also susceptible to biotransformation that reduces the systemic availability of the drug after percutaneous administration. However, it is important to recognize a substantial difference in first-pass metabolism that occurs in the skin compared with the usual organ of first-pass-the liver. A drug dose administered orally is dispersed throughout the liver before entering the systemic circulation, thereby accessing the full complement of liver enzymes. Drug applied to the skin is limited to a small region and exposed to a low fraction of the overall drug-metabolizing enzymes in skin. This process indicates that 1) saturation of metabolism in skin may be more likely to occur and 2) the overall impact of cutaneous first-pass is likely to be less than that observed for liver. Despite the readily recognized potential impact of drug biotransformation in the cutaneous environment, assessment of first-pass metabolism through the skin is difficult in vivo, especially because the metabolites generated in skin are not unique to this organ. Although studies in rhesus monkeys estimate that 15 to 20% of nitroglycerin is metabolized during first-pass through the skin, similar studies have not been conducted in man. At present, there is no experimental data that provides a careful estimate of the first-pass effect when drugs are applied to the skin.
Cutaneous Hypersensitivity. Many drugs are known to provoke immune responses in the skin when applied topically or administered systemically. Studies of contact sensitivity have shown the importance of immune events in the skin itself for the provocation of a hypersensitivity reaction in the skin (Khan et al., 2006) . Essential for initiation of such reactions is the activation of resident dendritic cells (i.e., LCs). Induction of oxidative stress, such as that seen upon exposure to reactive metabolites, may provide important LC activation signals (Sanderson et al., 2007) . Therefore, it has been postulated that bioactivation in the skin may be a critical step in the development of skin reactions after the systemic administration of drugs (Reilly et al., 2000; . Figure 1 presents the critical events believed to be essential for the provocation of a cutaneous immune response to drugs. Two critical steps in this process are the formation of neoantigens via protein haptenation and the activation of LCs. Whereas reactive metabolites that are formed in the liver could be transported to the cutaneous environment, the reactivity of such metabolites suggests that local bioactivation may be more important for the initiation of such reactions. Among agents that are associated with skin reactions, sulfamethoxazole and dapsone have been most widely studied in terms of cutaneous metabolism. The evidence described previously indicates that these drugs undergo bioactivation in skin cells and haptenated proteins, suggesting that the first steps in the initiation of these reactions can occur in the cutaneous environment. Additional studies have demonstrated that the arylhydroxylamine metabolites of these two drugs may induce oxidative stress and activate important danger signals in relevant skin cells Khan et al., 2007; Sanderson et al., 2007) . Whereas studies that demonstrate the biotransformation of drugs associated with skin rashes in skin or skin cells are supportive of this hypothesis, direct evidence for the role of skin-mediated biotransformation in vivo remains to be provided.
Conclusion
Substantial evidence has been provided to support the assertion that the biotransformation of drugs occurs in human skin and that this biotransformation may have significant implications. Of greatest importance to date is the topical application of prodrugs, whose beneficial effects on the skin would not occur in the absence of such biotransformation. Less clear is the significance of cutaneous biotransformation for drugs administered systemically. Thus, whereas the skin performs an important barrier function, it is similar to other organs of the body in that it is capable of a wide array of metabolic functions that may have a meaningful impact on drug therapy. The development of minimally invasive microdialysis techniques presents the opportunity to assess the quantitative significance of such metabolism and to confirm its occurrence in vivo.
